登录新浪财经APP 搜索【信披】查看更多考评等级 公司代码：603976 公司简称：正川股份 第一节 重要提示 1.1本半年度报告摘要来自半年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规 划，投资者应当到www.sse.com.cn网站仔细阅读半年度报告全文。 1.2本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确性、完整 性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 1.3公司全体董事出席董事会会议。 1.4本半年度报告未经审计。 1.5董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 第二节 公司基本情况 2.1公司简介 ■ 2.2主要财务数据 单位：元 币种：人民币 ■ 2.3前10名股东持股情况表 单位: 股 ■ 2.4截至报告期末的优先股股东总数、前10名优先股股东情况表 □适用 √不适用 2.5控股股东或实际控制人变更情况 □适用 √不适用 2.6在半年度报告批准报出日存续的债券情况 □适用 √不适用 第三节 重要事项 公司应当根据重要性原则，说明报告期内公司经营情况的重大变化，以及报告期内发生的对公司经营情 况有 ...

正川股份股价报22.24元，较前一交易日下跌0.62元，跌幅2.71%。开盘价为23.38元，最高价23.38元， 最低价22.06元，成交量为42569手，成交额0.96亿元。 8月22日主力资金净流出656.59万元，占流通市值0.2%。近五日主力资金净流出639.41万元，占流通市 值0.19%。 风险提示：投资有风险，入市需谨慎。 正川股份主要从事药用玻璃管制瓶等药用包装材料的研发、生产和销售。公司产品线覆盖0.5ML至 10ML等各类规格，包括预灌封注射器、卡式瓶、免洗免灭西林瓶等高附加值产品。公司业务涉及医疗 器械领域，注册地位于重庆。 公司2025年半年报显示，上半年实现营业收入3.24亿元，归母净利润1408.83万元。经营活动产生的现金 流量净额5936.13万元，同比增长89.31%。公司已在欧洲、南美、东南亚等近20个国家实现销售，并计 划在香港设立全资子公司以拓展国际市场。报告期内，公司新兴业务产销量较去年同期显著增长。 ...

重庆正川医药包装材料股份有限公司2025 年半年度报告 公司代码：603976 公司简称：正川股份 重庆正川医药包装材料股份有限公司 重庆正川医药包装材料股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人邓勇、主管会计工作负责人邓勇及会计机构负责人（会计主管人员）肖汉容声 明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告所涉及的未来计划、发展战略等前瞻性陈述，不构成公司对投资者的实质承诺，请投 资者注意投资风险。 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风险提示 公司已在本报告中详细 ...

证券代码：603976 证券简称：正川股份 公告编号：2025-053 债券代码：113624 债券简称：正川转债 重庆正川医药包装材料股份有限公司 关于 2025 年度"提质增效重回报"行动方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重庆正川医药包装材料股份有限公司（以下简称"公司"）为深入贯彻落实 国务院《关于进一步提高上市公司质量的意见》《关于加强监管防范风险推动资 本市场高质量发展的若干意见》要求，积极响应上海证券交易所《关于开展沪市 公司"提质增效重回报"专项行动倡议》，推动公司向高质量发展，切实保障和 维护投资者合法权益，进一步增强投资者信心，结合公司实际，制定了《2025 年度"提质增效重回报"行动方案》，本方案已经公司四届董事会第二十三次会 议审议通过，具体如下： 一、聚焦主业发展，提升经营质量 公司始终聚焦于药用玻璃管制瓶等药用包装材料的研发、生产和销售，公司 是国内药用玻璃行业中同时具备技术、人才、自动化生产及完整的"拉管--制瓶 —制盖"一体化生产企业，具备长期在该领域发展的核心竞争力。公 ...

Core Viewpoint - Zhengchuan Co., Ltd. has a closing price of 21.79 yuan, with a rolling PE ratio of 76.42 times, indicating a higher valuation compared to the industry average [1] Company Summary - Zhengchuan Co., Ltd. specializes in the research, production, and sales of pharmaceutical packaging materials, including borosilicate glass tubes and pre-filled syringes [1] - The company is a member of the China Pharmaceutical Packaging Association and the National Packaging Standardization Technical Committee [1] - As of March 31, 2025, the number of shareholders is 18,803, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Financial Performance - In the first quarter of 2025, the company reported revenue of 162 million yuan, a year-on-year decrease of 34.24%, and a net profit of 10.91 million yuan, down 48.15% year-on-year [1] - The sales gross margin for the same period is 21.61% [1] Industry Summary - The average PE ratio for the medical device industry is 56.58 times, with a median of 39.97 times, placing Zhengchuan Co., Ltd. at the 96th position in the industry ranking [1][2] - The industry includes various companies with lower PE ratios, such as Jiuan Medical at 11.36 times and Yuyue Medical at 20.20 times [2]

Company Overview - Zhengchuan Co., Ltd. closed at 22.31 yuan, down 1.85%, with a rolling PE ratio of 78.24 times and a total market value of 3.373 billion yuan [1] - The company operates in the pharmaceutical packaging materials sector, focusing on the research, production, and sales of medicinal glass tubes and other packaging materials [1] - Main products include borosilicate glass tubes, soda-lime glass tubes, aluminum caps, pre-filled syringes, and cassette bottles [1] Financial Performance - For Q1 2025, the company reported revenue of 162 million yuan, a year-on-year decrease of 34.24%, and a net profit of 10.9141 million yuan, down 48.15% year-on-year, with a gross margin of 21.61% [1] Shareholder Information - As of March 31, 2025, the number of shareholders was 18,803, a decrease of 638 from the previous period, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Industry Comparison - The average PE ratio for the medical device industry is 57.51 times, with a median of 41.25 times, placing Zhengchuan Co., Ltd. at the 96th position in the industry ranking [1][2] - Other companies in the industry have varying PE ratios, with the highest being 21.19 times for Antu Biology and the lowest at 11.26 times for Jiuan Medical [2]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Zhengchuan Co., which is currently facing a decline in stock price and profitability [1][2] - As of August 4, Zhengchuan Co. closed at 22.56 yuan, down 3.18%, with a rolling PE ratio of 79.12 times, significantly higher than the industry average of 54.32 times [1] - The company's total market capitalization is 3.411 billion yuan, ranking 99th in the medical device industry based on PE ratio [1][2] Group 2 - Zhengchuan Co. reported a revenue of 162 million yuan for Q1 2025, reflecting a year-on-year decrease of 34.24%, and a net profit of 10.91 million yuan, down 48.15% year-on-year [1] - The company's sales gross margin stands at 21.61% [1] - Zhengchuan Co. specializes in the research, production, and sales of pharmaceutical packaging materials, including borosilicate glass tubes and pre-filled syringes [1]

Company Overview - Zhengchuan Co., Ltd. closed at 23.3 yuan, down 2.18%, with a rolling PE ratio of 81.71 times and a total market value of 3.523 billion yuan [1] - The company specializes in the research, production, and sales of pharmaceutical packaging materials, including borosilicate glass vials and sodium-calcium glass vials [1] - Zhengchuan is a member of the China Pharmaceutical Packaging Association and the National Packaging Standardization Technical Committee [1] Financial Performance - For Q1 2025, the company reported revenue of 162 million yuan, a year-on-year decrease of 34.24%, and a net profit of 10.9141 million yuan, down 48.15% [1] - The sales gross margin for the same period was 21.61% [1] Shareholder Information - As of March 31, 2025, the number of shareholders was 18,803, a decrease of 638 from the previous period, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Industry Comparison - The average PE ratio for the medical device industry is 53.65 times, with a median of 37.22 times, placing Zhengchuan at the 101st position in the industry ranking [1][2] - The industry includes various companies with lower PE ratios, such as Jiuan Medical at 11.01 times and Yingke Medical at 15.45 times [2]

Company Overview - Zhengchuan Co., Ltd. closed at 22.18 yuan, down 3.61%, with a rolling PE ratio of 77.78 times and a total market value of 3.354 billion yuan [1] - The company specializes in the research, production, and sales of pharmaceutical packaging materials, including borosilicate glass tubes and pre-filled syringes [1] Financial Performance - For Q1 2025, the company reported revenue of 162 million yuan, a year-on-year decrease of 34.24%, and a net profit of 10.9141 million yuan, down 48.15% year-on-year, with a gross margin of 21.61% [1] Shareholder Information - As of March 31, 2025, the number of shareholders was 18,803, a decrease of 638 from the previous period, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Industry Comparison - The average PE ratio for the medical device industry is 55.46 times, with a median of 37.74 times, placing Zhengchuan Co., Ltd. at 98th in the industry ranking [1][2] - The industry average market value is 11.547 billion yuan, while the median is 5.685 billion yuan [2]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Zhengchuan Co., which has a current stock price of 23.01 yuan, up 6.68%, with a rolling PE ratio of 80.69, marking a new low in 635 days, and a total market capitalization of 3.479 billion yuan [1] - Zhengchuan Co. ranks 100th in the medical device industry, which has an average PE ratio of 55.28 and a median of 38.06 [1][2] - As of March 31, 2025, Zhengchuan Co. has 18,803 shareholders, a decrease of 638 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2 - The main business of Chongqing Zhengchuan Pharmaceutical Packaging Materials Co., Ltd. includes the research, production, and sales of pharmaceutical packaging materials such as borosilicate glass tubes and sodium-calcium glass tubes [1] - The latest quarterly report for 2025 shows that the company achieved an operating income of 162 million yuan, a year-on-year decrease of 34.24%, and a net profit of 10.9141 million yuan, down 48.15%, with a sales gross margin of 21.61% [1]